Uy Ear
Stock Analyst at Mizuho
(3.99)
# 618
Out of 4,711 analysts
58
Total ratings
42.42%
Success rate
16.99%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Maintains: Neutral | $7 → $20 | $16.98 | +17.79% | 4 | Dec 19, 2024 | |
| RLMD Relmada Therapeutics | Downgrades: Neutral | $23 → $1 | $0.36 | +175.56% | 1 | Dec 5, 2024 | |
| ALKS Alkermes | Maintains: Outperform | $35 → $40 | $29.71 | +34.63% | 5 | Nov 13, 2024 | |
| SAGE Sage Therapeutics | Maintains: Neutral | $18 → $16 | $5.61 | +185.20% | 2 | Jul 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $40 | $19.02 | +110.30% | 1 | May 24, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $145 → $179 | $118.97 | +50.46% | 5 | May 17, 2024 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $17 → $18 | $14.99 | +20.08% | 12 | May 15, 2024 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $25 → $21 | $16.87 | +24.48% | 10 | May 9, 2024 | |
| EOLS Evolus | Maintains: Buy | $20 → $23 | $10.89 | +111.20% | 3 | Mar 8, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Neutral | $116 → $140 | $135.42 | +3.38% | 10 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $16 | $3.09 | +417.80% | 1 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $144.47 | -72.31% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.38 | +320.17% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $0.77 | +287.45% | 2 | Mar 1, 2023 |
uniQure
Dec 19, 2024
Maintains: Neutral
Price Target: $7 → $20
Current: $16.98
Upside: +17.79%
Relmada Therapeutics
Dec 5, 2024
Downgrades: Neutral
Price Target: $23 → $1
Current: $0.36
Upside: +175.56%
Alkermes
Nov 13, 2024
Maintains: Outperform
Price Target: $35 → $40
Current: $29.71
Upside: +34.63%
Sage Therapeutics
Jul 19, 2024
Maintains: Neutral
Price Target: $18 → $16
Current: $5.61
Upside: +185.20%
Cartesian Therapeutics
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $19.02
Upside: +110.30%
Sarepta Therapeutics
May 17, 2024
Maintains: Buy
Price Target: $145 → $179
Current: $118.97
Upside: +50.46%
Arcutis Biotherapeutics
May 15, 2024
Maintains: Buy
Price Target: $17 → $18
Current: $14.99
Upside: +20.08%
ACADIA Pharmaceuticals
May 9, 2024
Maintains: Neutral
Price Target: $25 → $21
Current: $16.87
Upside: +24.48%
Evolus
Mar 8, 2024
Maintains: Buy
Price Target: $20 → $23
Current: $10.89
Upside: +111.20%
Neurocrine Biosciences
Feb 8, 2024
Maintains: Neutral
Price Target: $116 → $140
Current: $135.42
Upside: +3.38%
Nov 22, 2023
Maintains: Buy
Price Target: $35 → $16
Current: $3.09
Upside: +417.80%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $144.47
Upside: -72.31%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $2.38
Upside: +320.17%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $0.77
Upside: +287.45%